Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
First results of DREAM trial of frontline durvalumab for mesothelioma

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.18
Views: 1153

Prof Anna Nowak - The University of Western Australia, Perth, Australia

Dr Nowak speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the DREAM trial comparing durvalumab as a first line treatment for mesothelioma patients compared to platinum-based chemotherapy.

She outlines the current patient cohort and treatment schedules for the study arms, and notes the impact of durvalumab on patients progression free survival at 6 months.

Dr Nowak also discusses the toxicity profile of frontline durvalumab, with 3 grade 3 events and 4 non-trial related deaths.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation